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Access site management with vascular closure
devices for percutaneous transarterial procedures
Carlos F. Bechara, MD, Suman Annambhotla, MD, and Peter H. Lin, MD, Houston, Tex
The rising numbers in the aging population will undoubtedly lead to a corresponding increase in percutaneous
endovascular procedures to address their cardiovascular health issues. With a constant drive to develop innovative
treatment methods to achieve improved treatment outcomes while reducing procedural-related complications, endovas-
cular interventionalists have focused on technologies to provide efficient hemostatic control of femoral artery access
following percutaneous diagnostic or therapeutic angiographic procedures. Compared with the traditional hemostatic
method using manual compression, several arterial closure devices (ACD) have been shown to reduce time of hemostasis,
enable early patient ambulation, reduce hospitalization staff use, and improve patient outcome. However, these ACDs
have their shortcomings as the interventionalists need to be familiar with these technologies as well as their potential
complications. This article provides a comprehensive review of current closure device technologies as well as clinical
experiences with these devices. The adjunctive role of these technologies in endovascular aortic aneurysm repair is also
discussed. (J Vasc Surg 2010;52:1682-96.)As the aging population continues to rise, there is a
corresponding increase in the number of percutaneous
radiologic and endovascular procedures to address their
cardiovascular health issues. According to theUnited States
Census Bureau, there will be 71 million people above the
age of 65 years, and 19.5 million above the age of 80, ie, a
7% and 50% rise in 2030 compared with year 2000,
respectively. Cardiovascular disease is the number one
cause of death in the United States. Consequently, there is
a constant drive to develop innovative methods and devices
that enable interventionalists to achieve diagnostic or ther-
apeutic goals while reducing procedural related risks and
enhancing patient satisfaction, and performing outpatient
procedures. One area of percutaneous vascular interven-
tions, which has received intense focus in the past decade
relates to technologies to achieve rapid and effective con-
trol of femoral arterial access, which is traditionally accom-
plished by manual compression. These arterial closure
devices (ACD) have been shown to reduce time of hemosta-
sis, enable early patient ambulation, reduce hospitalization
staff utilization, and improve patient outcome.1 However,
these ACD have their shortcomings and the interventionalists
need to know about these devices, how they work, and their
potential complications.Minor andmajor complications have
been reported from 1.5% to 9% 2,3 with up to 40% requiring
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1682surgical repair. Table I lists some of the complications re-
ported with ACD use.
First introduced in conjunction with the Seldinger
percutaneous puncture technique, manual compression
(MC) has been regarded as the standard method to achieve
hemostasis following percutaneous procedures for nearly
five decades. Manual compression is performed with sus-
tained pressure over the puncture site for 15 to 20 minutes
followed by bed rest for an additional 6 hours. While this
technique is sufficient in achieving groin hemostasis in the
majority of patients undergoing percutaneous procedures,
manual compression may not be effective in providing
sustainable hemostatic pressure in obese patients. Addi-
tionally, patients with certain medical comorbidities related
to lumbar or pelvis ailments may encounter difficulty with
prolonged immobilization. With increased utilization of
various anticoagulation regimens during percutaneous in-
terventions, including antiplatelet glycoprotein IIb/IIIa
inhibitors, groin-bleeding complications with MC have
similarly risen sharply.4,5
The shortcomings related to manual compression cou-
pled with efforts to improve post-catheterization hemosta-
sis have led researchers to develop a variety of vascular closure
devices in the past decade. The primary advantage attributed
to VCD is shortened duration to achieve hemostasis and
avoidance of prolonged immobilization so that earlier ambu-
lation and outpatient discharge can be achieved following
percutaneous procedures.
There are no large randomized clinical trials comparing
ACD vs manual compression (MC), but two meta-analyses
showed marginal or no benefit of ACD over MC.1,2 How-
ever, there was significant heterogeneity of the studies
reviewed in these meta-analyses in the setting with which
the ACDwere used, as well as the patients and the operator.
In addition, most MC was done after reversal of activated
clotting time (ACT), while ACD were deployed regardless
of anticoagulation status. Strategies to reduce vascular
complications with ACD have been effective and showed
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generation devices have been revised and improved with
fewer complications reported.3,6
This article provides an overview of the technologies
available as an alternative toMC to achieve hemostasis after
percutaneous catheterization procedures. Clinical data to
support their utility and compare them with MC, as well as
complications related to these closure devices are also dis-
cussed.
OVERVIEW OF VASCULAR CLOSURE DEVICES
Significant advances have occurred in the past decades
in vascular closure technologies leading to several impor-
tant design features that merit consideration when choos-
ing a vascular closure device. There is no ideal device; each
one has its own inherent problems. Despite the advances
made to improve these ACD, their use did not increase
rapidly, some reporting only one-third utilizing it after a
diagnostic catheterization.8 This is due to lack of superior-
ity of ACD over MC, concern for cost, and lack of reim-
bursement.
Ideally, a closure device should be simple to use with-
out cumbersome deployment mechanism and should be
safe. The activation of the device closure mechanism should
be reliable and consistent with low complication rates com-
parable to traditional manual compression methods. The
utilization of a closure device should not incite significant
inflammatory reaction in the surrounding tissue. The latter
feature allows procedural safety if postinterventional repeat
puncture or surgical access is necessary. Lastly, an ideal
device must be cost effective. Cost-effectiveness is a tough
issue to decipher; it depends not only on cost but also on
reimbursement, on the reduction of cost related to compli-
cations as well as comparison to what mechanism of exter-
nal compression is used as MC. Using a C-clamp or other
similar device is cheaper than a staffing personal putting
external pressure. There are no CPT codes for reimburse-
ment; the codes available for ACD are codes used by
physicians and institutions to report or track their use. Cost
reduction driven by reduction in vascular complications is
small especially in patients undergoing diagnostic proce-
Table I. Complications of arterial closure devices
Infection
Bleeding (minor, major)
Groin hematoma (minor, major)
Retroperitoneal bleed
Pseudoaneurysm
Arterial laceration
Arteriovenous fistula
Embolization
Limb ischemia
Femoral artery thrombosis
Dissection
Pain
Nerve injury
Deathdures where the complication rate is lower.3,8 All thesedifferent factors make the cost-effectiveness calculation
very complex and difficult. A small randomized trial com-
paring ACD with MC showed a modest reduction in hos-
pital stay of 70 euro per patient.9 This cost saving could
be potentially lost if a fem-stop or similar device was used,
which is cheaper than a nurse or health personnel applying
MC.
Based on the mechanism and technology utilized by
these devices to achieve hemostasis, they can be divided
into three broad categories. They include (1) collagen-
based technology, (2) suture-mediated technology, and (3)
staple or clip-based technology. Commonly used vascular
closure devices based on these three mechanisms are listed
in Table II.
COLLAGEN-BASED VASCULAR DEVICES
Devices that utilize collagen to achieve hemostasis are
primarily based on bovine biodegradable products to aug-
ment thrombus formation. The hemostatic formation of
collagen-based closure devices is based on two biochemical
reactions. The collagen plug is deployed outside the vessel
wall on the arteriotomy site. This exogenous collagen ma-
terial forms an extracellular lattice, which triggers a hemo-
static cascade by promoting platelet aggregation, adher-
ence, and activation.10 Secondly, upon contact with blood,
the collagen expands its physical mass resulting in mechan-
ical occlusion of the vessel puncture site and tissue tract.11
Because of the degradable nature of these proteinaceous
bioproducts , the resorption of these collagens may lead to
varying degrees of inflammatory processes in the surround-
ing soft tissue.12 Repeat puncture or surgical exploration of
the same artery may lead to increased difficulty due to
subcutaneous inflammatory tissue reaction. In vivo studies
have shown that collagen plugs are resorbed within 4
weeks, which subsequently leads to the recommendation
that repeat access or surgical exploration of the same vessel
should not be performed for 4 weeks following the deploy-
ment of the collagen-based devices.4,10,13 Common exam-
ples of these collagen-based closure devices include Angio-
Seal (St Jude Medical, St Paul, Minn), VasoSeal (St Jude
Medical), and Duett (Vascular Solutions, Minneapolis,
Minn).
Angio-Seal. The Angio-Seal (St Jude Medical) re-
ceived its initial approval from the Food and Drug Admin-
istration (FDA) in 1996. With more than 7 million devices
distributed worldwide since its introduction, Angio-Seal is
one of the most widely used arterial closure devices. This
device went through multiple revisions, and the current
one is very user friendly. This is a bioabsorbable collagen
closure device, which consists of an absorbable, intra-
arterial anchor, a small bovine collagen plug, and an ab-
sorbable traction suture (Fig 1).14,15 At the completion of
the percutaneous angiography, the anchor and collagen
plug are inserted into the artery through a specially de-
signed sheath and then pulled up snugly against the arterial
wall to seal the puncture site. The intra-arterial anchor is a
T-shaped material composed of copolymers of polylactic
and polyglycolic acids. When deployed, the combination of
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sandwiches the puncture site between the anchor and the
extravascular collagen plug to seal the arterial puncture site.
The Angio-Seal is available in a 6F or 8F system. Femoral
arteriography is recommended prior to device deployment
as calcified vessel walls may preclude safe device anchor
Table II. Summary of current vascular closure devices
Device category Device name Manufacturer
Recommende
sheath size (F
Collagen-based
device
Angio-Seal VIP,
Angio-Seal
STS Plus
St Jude Medical 6, 8
Angio-Seal
Evolution
St Jude Medical 4-8
VasoSeal VHD,
ES, Elite
St Jude Medical 5-8
VasoSeal Low
Profile
St Jude Medical 4, 5
Duett Pro,
Duet
Vascular
Solutions
5-9
Suture-based
device
Perclose A-T Abbott Vascular 5-8
Perclose
ProGlide
Abbott Vascular 5-8
Prostar XL Abbott Vascular 8.5-10
X-Site St Jude Medical 5, 6
SuperStitch Sutura 6-12
Metal clip or
disc-based
device
StarClose Abbott Vascular 5, 6
StarClose SE Abbott Vascular 5, 6
Angiolink EVS Medtronic 6-8
Boomerang Cordiva 4-10deployment and device activation. Additionally, angio-graphic confirmation of the puncture site is necessary, as
the device should not be deployed in the external iliac
artery, superficial femoral artery, or profunda femoris ar-
tery. Another consideration to avoid the use of this device is
in peripheral vascular disease patients and vessels less than 5
mm in diameter. The intraluminal anchor and collagen
aximum wire
compatibility
(inch) Comments
0.038 These are earlier versions of Angio-Seal family,
which deliver collagen plugs to close the
arteriotomy. Collagens are reabsorbed
within 90 days. Device application allows
for immediate repeat access.
0.038 This is most recent generation of Angio-Seal,
which creates an automated collagen
compaction. All components are reabsorbed
within 90 days. Device application allows
for immediate repeat access.
0.038 These devices do not leave any intravascular
collagen component. The collagen is
deposited in extravascular space, which is
bioabsorbable.
0.038 This is designed to accommodate smaller
sheaths including 4F or 5F puncture sites.
vice is delivered
through existing
sheath
This device uses thrombin and collagen
procoagulant solution, which is delivered
through existing sheath. A balloon catheter
is also utilized to aid hemostasis. Duett Pro
is approved for use in patients with GP IIb/
IIIa inhibitors.
0.038 This is an early version of Perclose family,
which deploys braided polyester sutures.
0.038 This device delivers a monofilament
polypropylene suture with automated knot
creation.
0.038 Commonly used for procedures requiring
large introducer sheaths, such as
endovascular aortic aneurysm procedure.
The device uses braided polyester suture for
arteriotomy closure.
0.038 The device delivers a braided polyester suture
with automated suture knot creation. Its
clinical applicability is compared less with
Perclose family since it is only approved for
5F and 6F puncture sites.
0.038 This device uses polyprolyene suture and
delivers through existing sheath. It is
available in 12F introducer sheath size.
0.038 This is the first generation of StarClose family,
which delivers an extravascular nitinol clip
that mechanically approximates the
arteriotomy.
0.038 This is the second generation of StarClose
family with improved ease-of-use design.
0.038 This device delivers an extraluminal titanium
staple at the adventitial layer for arteriotomy
closure.
0.038 This device uses a nitinol-based wire with a
temporary nitinol braided mesh disc to
achieve hemostasis. No foreign materials are
left in intraluminal or extraluminal space.d
)
M
Deplug are absorbed within 30 days. Therefore, vessels should
JOURNAL OF VASCULAR SURGERY
Volume 52, Number 6 Bechara et al 1685not be accessed for 1 month following placement of an
Angio-Seal device. If reaccess is needed, then it can be done
1 cm above the previous access site.16 Similarly, if surgical
exploration or femoral revascularization is a possibility fol-
lowing arteriography, this type of bioabsorbable collagen
device should not be utilized. If device deployment fails,
hemostasis can still be achieved with manual compression.
Infrequent complications such as acute femoral artery
thrombosis can occur due to inadvertent plug deployment
within the intraluminal space, which will necessitate urgent
surgical exploration and plug removal (Fig 2).
VasoSeal. The VasoSeal (St Jude Medical, St Paul,
Minn), is a closure device utilizing a purified bovine collagen-
based plug to achieve hemostasis at the arterial punctured
site (Fig 3). Since the first generation of the VasoSeal device
was approved by the FDA in 1995, there have been a total
of four different platforms of VasoSeal which include (1)
VasoSeal Vascular Hemostasis Device (VHD), (2) VasoSeal
ES (Extravascular Security), (3) VasoSeal Low Profile, and
(4) VasoSeal Elite.17,18 These various platforms are in-
tended to be used for varying diameters of the arterial
punctured site. Both VasoSeal Elite and ES utilize a tem-
porary J-shaped locator segment, which is deployed so the
collagen plug is deposited on the outer surface of the vessel
wall along the puncture tract. The main difference between
the Angio-Seal and VasoSeal is that the latter device does
not possess any intraluminal components, while an Angio-
Seal deploys an intraluminal plug to achieve hemostasis.
The VasoSeal devicemay be used with themaximum sheath
Fig 1. Deployment of Angio-Seal closure device. A, Th
guidewire. It is advanced until blood flows out through t
blood flow ceases and is advanced until the blood flow re
is inserted fully into the sheath with two arrows on the s
released beyond the sheath tip. The barrel of the device
then withdrawn. The anchor will be fixed against the ins
on the suture as the sheath is removed. C, Once fully v
collagen plug, which becomes compressed against the pu
tamper is removed.size of 8F introducer sheath. Following the VasoSeal devicedeployment, patients only need to remain in bed rest for 1
hour before they can be ambulatory. Repeat arterial punc-
ture can be performed after 6 weeks of deployment of the
VasoSeal device. Because this device deploys an extralumi-
nal collagen plug, femoral artery calcification or peripheral
artery disease is not considered a contraindication for Va-
soSeal deployment. Also, there is no need for a femoral
io-Seal sheath is placed within the vessel via the existing
it hole in the dilator as shown. It is then withdrawn until
B, Locator and guidewire are removed. The Angio-Seal
and device assembly meeting. The anchor will then be
racted with a double “click,” and the whole assembly is
f the vessel by gentle traction. A tamper becomes visible
, the tamper is advanced forward to tie a knot over the
re site. The suture is then cut above the tamper, and the
Fig 2. Groin exploration after a young female complained of
right leg claudication subsequent to intracranial aneurysm embo-
lization. Angio-Seal was used for arteriotomy closure, which re-
sulted in inadvertent plug deployment within the intraluminal
space. The plug was removed and the femoral artery repaired with
bovine patch angioplasty.e Ang
he ex
starts.
heath
is ret
ide o
isible
nctuangiogram prior to deployment. However, the VasoSeal
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length limitations.
Because the collagen plug is deployed in the extralumi-
nal space, patients frequently experience an irritated skin
lump due in part to the inflammatory reaction caused by the
collagen plug resorption. The manufacturer has addressed
this issue by reducing the amount of bovine collagen in-
serted in later versions of the device. In the event of device
deployment failure, hemostasis of the arterial puncture can
be remedied with the conventional manual compression.
Infrequent complications such as acute femoral artery
thrombosis can occur due to inadvertent plug deployment
within the intraluminal space, which will necessitate urgent
surgical thrombectomy and plug removal.
Duett device. The Duett sealing device (Vascular So-
lutions) combines the procoagulant effect of thrombin with
the platelet activation of collagen plus a 3F balloon cathe-
ter. This closure technology is based on an extraluminally
placed collagen-based hemostatic component. The balloon
catheter is first deployed through any existing 5F to 9F
vascular sheath. The catheter is subsequently delivered into
the artery, which is followed by the inflation of a 3 mm 7
mmballoon (Fig 4). The inflated balloon is then withdrawn
anteriorly against the intraluminal surface of the arteriot-
Fig 3. Deployment of VasoSeal closure device. A, The
sheath. B, With occlusive pressure above the arteriotomy
J-segment is deployed. The entire segment is retracted u
followed by the blue sheath dilator, until a marker indic
dilator are removed, leaving only the outer sheath. The c
advanced initially; then the sheath is retracted to fully dep
applied to the skin until hemostasis is achieved.omy to create a temporary puncture site hemostasis. This isfollowed by the injection of procoagulant agents into the
sidearm of the sheath as it is slowly withdrawn. Continual
infusion of the procoagulant while the sheath is withdrawn
triggers an accelerated clotting cascade and platelet activa-
tion to close the subcutaneous tract. This cascade is char-
acterized by the conversion of fibrinogen into fibrin by the
action of thrombin in the presence of collagen resulting in
accelerated coagulation reaction. The balloon is lastly de-
flated and withdrawn completely from the puncture site.
This is a low profile catheter and does not disrupt the plug
upon removal. Additional manual compression for 3 min-
utes is necessary to achieve hemostasis.19
Similar to the VasoSeal device, there is no intraluminal
anchor. The Duett device has been shown to be effective in
achieving satisfactory hemostasis and early ambulation
compared with manual compression.19-21 Vessels, which
have been treated with the Duett closure device, can un-
dergo repeated puncture immediately for angiography and
cause minimal local inflammation. Potential accidental in-
jection of collagen into intraluminal space can occur due to
suboptimal balloon inflation. This could happen in periph-
eral artery disease patients where the balloon gets stuck to
the posterior plaque and does not seal the arteriotomy from
the thrombin injection. Consequently, one potential com-
tomy locator is inserted through an introducer into the
sheath is removed, and the locator is retracted until the
esistance is felt. C, The white tissue dilator is advanced,
the tip is at the arteriotomy site. D, Locator and tissue
n cartridge is inserted into the sheath and the plunger is
he collagen plug. The sheath is removed, and pressure isarterio
, the
ntil r
ates
ollage
loy tplication of the Duett device is that of inadvertent infusion
for
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acute arterial thrombosis.13 This complication has been
treated with either thrombolysis or thrombectomy.
SUTURE-BASED VASCULAR CLOSURE
DEVICES
These devices achieve arterial hemostasis by deploying
sutures, which are tied to form a surgical knot to close the
arteriotomy. The knot is tied by a built-in mechanism
within the closure device, but can also be tied manually if
necessary. Because there is no proteinaceous biomaterial
left behind in the puncture tract, there is no bioresorption
or inflammatory soft tissue reaction associated with this
closure technology. Consequently, repeat arterial access or
immediate surgical exploration of the same artery can be
performed safely. Common examples of these suture-based
closure devices include Perclose (Abbott Vascular Devices,
Redwood City, Calif), X-Site (Datascope, Montvale, NJ),
and SuperStitch (Sutura, Fountain Valley, Calif).
A list of these suture-based closure devices is provided
in Table II.
Perclose device. The Perclose device (Abbott Vascu-
lar Devices) was the first suture mediated closure system
approved by the FDA in 1997. There are various Perclose
platforms including (1) the ProGlide, (2) Perclose A-T, (3)
Closer S, and (4) Prostar XL, which can deploy single or
double nonabsorbable sutures and are intended for various
introducer sheath sizes ranging from 6F to 10F. These
devices differ in the sheath size, suture type, and suture
deployment. To deploy the Perclose device, it is first ad-
vanced into the artery over a guidewire. After proper posi-
tioning, a braided 3-0 polyester suture is deployed, and the
device is removed after the knot has been tightened down
around the puncture site (Fig 5). The Prostar XL device was
the earliest version, which utilizes a series of complex
mechanisms that involve the delivery of either 2 or 4
needles from inside of the artery. These suture-attached
Fig 4. Deployment of the Duett closure device.A,The
a balloon at its tip. The balloon is inflated with a syringe a
site. B, Procoagulant mixture is then delivered through t
as the sheath is retracted. The entire subcutaneous tract
catheter and sheath are removed. The skin is compressedneedles are punctured across the artery, which are engagedby the barrel of the delivery system. Once engaged in the
arterial wall, the sutures are manually tied in a conventional
surgical slipknot, which is pushed down toward the surface
of the arteriotomy to achieve suture-mediated closure.4,22
These devices were not popular because the operator
needs to form and push down the knot. The newer devices
have a pretied knot. The recent platforms of Perclose
devices, including the ProGlide, Perclose A-T, and Closer,
are based on a different design in which needles are de-
ployed from outside the vessel and the device captures the
suture immediately. The Closer device requires the opera-
tor to tie the suturemanually, while the Perclose A-T device
already has a pretied knot. The Closer and A-T device may
be utilized to achieve hemostasis following the use of 5F to
8F sheaths. Similar to the Angio-Seal system, the Perclose
device provides arterial anchoring to achieve hemostasis,
which is a beneficial feature in patients who receive antico-
agulants. Similar to the Duett device, the Perclose system
can be applied in the same artery immediately following its
deployment. Unlike all other collagen-based closure sys-
tems, the closure mechanism in the Perclose device, which
is based on a monofilament polypropylene suture, repre-
sents a permanent foreign material in the extravascular
space.
X-press device. The X-press device (X-Site) was a
recently introduced suture-mediated closure device. This
device consists of three mechanical components to achieve
hemostasis, which includes an over-the-wire device, a su-
ture attached to two needles, and a knot pusher, which also
functions as a suture cutter. Unlike the Perclose device, the
X-Site system contains no intra-arterial component for
suture-mediated closure. Deployment of this device in-
volves sequential engagement of the first needle with a
subsequent 180° twist, which is followed by the deploy-
ment of the second needle. The sutured knot is then tied
down manually or by using a knot tier. Unlike the Perclose
theter is advanced through the working sheath which has
retracted until it engages the arterial wall at the puncture
eath side arm directly to the puncture site and continued
d and thrombosed. C, The balloon is deflated, and the
2 to 5 minutes.3F ca
nd is
he sh
is filledevice, which has a wide range of applicability of various
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sheaths up to 6F in size.
SuperStitch device. The SuperStitch device (Sutura)
is also a recently introduced suture-mediated closure de-
vice, which utilizes nonabsorbable monofilament polypro-
pylene sutures to close the arterial puncture site. The device
can be deployed through a conventional access sheath and
is advanced without wire guidance. To deploy the sutures,
three buttons on the body of the device are activated in a
sequential fashion to initiate the suture-mediated closure
mechanism (Fig 6). A unique feature of this device is that it
can be used to close arterial punctures even in an antegrade
approach. Because of its relatively short history in commer-
cial applications, there is no large series of clinical data
comparing this device with other suture-based closure de-
vices.
METAL CLIP OR DISC-BASED VASCULAR
CLOSURE DEVICE
Devices, which utilize metal clip-based technology,
Fig 5. Deployment of the Perclose closure device. A, Insertion
and positioning of the 6F Perclose device over the wire into the
femoral access site until pulsatile flow through the marker lumen is
seen indicating an adequate intraluminal device position. B, De-
ployment of foot and positioning against the arterial wall by pulling
the device upward in preparation for needle deployment. Sutures
are deployed around the arteriotomy and are pulled from the
device outside the skin.C, The pre-tied knot is pushed down using
the knot pusher that comes with the device. Once hemostasis is
achieved, the suture is cut using a knot cutter. The final suture lies
securely around the arteriotomy to achieve hemostasis.deploy either metal staple or clip that penetrates the vesselwall to achieve hemostasis. Upon deployment, the metal
clip or staple remains in situ over the vessel wall and forms
a geometric configuration that approximates adventitial
vessel layers to close the arterial hole. Unlike the collagen-
based devices, these metallic clips or staples do not undergo
a bioresorption reaction, which therefore does not trigger
significant soft tissue inflammatory response. Repeat puncture
or surgical exploration of the artery can be done safely. Com-
mon examples of these closure devices include Angiolink EVS
Vascular Closure System (Medtronic) and StarClose (Abbott
Vascular). A list of these clip-based closure devices is provided
in Table II.
StarClose closure system. The StarClose device (Ab-
bott Vascular, Redwood City, Calif) features a 4-mm-
diameter, flexible nitinol clip, which is designed to close
femoral arteriotomies created by sheaths up to 6F in size.
The system consists of an introducer sheath, dilator, guide-
wire, and a clip applier. Activation of the locator button
deploys small flexible wings that form the locator. An
implantable nitinol clip is positioned in the clip applier.
When the device is activated, the nitinol staple is engaged in
the adventitial layer of the vessel whereby its tines grasp the
edges of arteriotomy and draw them together to close the
puncture hole (Fig 7). In contrast to collagen-based de-
vices, the nitinol used in the StarClose device is a widely
utilized metallic material commonly used in intra-arterial
stent or stent graft devices, which has a low profile in
bioreactivity in inducing inflammatory soft tissue reac-
tion.4,12
Angiolink EVS vascular closure system. The Angio-
link EVS Vascular Closure System (Medtronic, Santa Rosa,
Calif) deploys an extraluminal titanium staple to achieve
vascular hemostasis without penetrating all three layers of
an artery. Prior to the staple deployment, a series of vessel
stabilizers align the arteriotomy hole into a linear configu-
ration. A titanium staple is deployed at the adventitial layer,
which approximates the puncture site to achieve hemosta-
sis. Similar to the nitinol material of the StarClose device,
the inert properties of titanium in the Angiolink device
induces minimal biologic response or inflammatory tissue
reaction in comparison to collagen-based devices.4,12
Boomerang closure device. The Boomerang closure
device system (Cardiva Medical, Mountain View, Calif)
utilizes an 18-G conformable nitinol-based wire with a
temporary nitinol braided mesh disc on a tether which is
deployed inside the artery to achieve hemostasis. This de-
vice received an FDA approval in October 2004. It creates
a site-specific compression between the arteriotomy and
tissue tract, resulting in targeted internal compression. The
hemostatic mechanism is based on the recoiling of the
arteriotomy site, which is analogous to the “boomerang”
effect (Fig 8). After a few minutes of device deployment,
the nitinol mesh disc and wire are then removed, thus
leaving no foreign body in either intraluminal or extralumi-
nal space. This is then followed with 5 to 7 minutes of
manual compression over the remaining puncture site to
achieve complete hemostasis. The Boomerang device is
designed to close femoral arteriotomy created by sheaths
wall.
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success rate of 99% in achieving complete hemostasis with
an average time of 82 minutes from the end of device
application to ambulation.23 However, the need for man-
ual compression following the device application represents
a potential drawback of this particular device.
APPLICATION OF PERCLOSE DEVICE IN
ENDOVASCULAR STENT GRAFT PROCEDURE
While all available closure devices are effective in achieving
hemostasis for the conventional interventional vascular proce-
dure using either 5F or 6F introducer sheaths, the Perclose
Prostar device utilizes a unique suture-mediated technology,
which enables its application in percutaneous endovascular
aortic stent graft procedures where large introducer sheaths
up to 20F or 24F are routinely used. It is noteworthy that
Prostar XL is approved for arteriotomy closure created by a
10F sheath size. Several studies have reported various off-
Fig 6. Deployment of the SuperStitch closure device. A
button is depressed which opens out the suture arms. B,
button is depressed, which deploys the needles. D, Th
needles retract and draw the sutures out of the vessel. F, T
The Kwiknot ties and cuts the suture close to the vessellabel application of a “Preclose” technique or double de-ployment of either Prostar or Preclose devices to achieve
hemostasis following percutaneous interventional proce-
dures of sheath up to 24F in size.24-27 This “Preclose”
technique requires placement of two Perclose devices 90° to
each other at the beginning of the procedure leaving the knots
untied.24,25 Alternatively, a single Prostar XL can be used for
large introducer sheath applications. The puncture site is
then dilated to the appropriate size, and the sutures are
ultimately tied once the endovascular stent-graft procedure
is completed.27,28 This technique has been described in
percutaneous deployment of endovascular aortic grafts,
peripheral covered stents, and intra-aortic balloon pu-
mps.27,29 A brief description of this percutaneous tech-
nique using a single Prostar XL device for endovascular
aortic stent graft procedures is provided below.
To perform a percutaneous endovascular aortic repair
utilizing a Prostar XL device, it is important to first assess
the femoral artery using an ultrasound to determine its
device is advanced through an existing sheath. The first
device is retracted against the vessel wall. C, The second
d bottom is activated which closes the suture. E, The
not can be tied manually or by using the Kwiknot device., The
The
e thir
he kdiameter and associated vessel calcification. Only femoral
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ential calcification should be considered for this percutane-
ous approach. Fluoroscopic imaging is used to identify the
femoral head and an Ultrasound-guidance access of the
common femoral artery is obtained percutaneously in
which a 6F sheath is inserted. A 1-cm incision is created
next around the sheath, with blunt dissection of the subcu-
taneous tissue. The sheath is removed over the wire and a
10-F Prostar XL device is advanced into the common
femoral artery with the tip placed in the distal aorta (Fig 9).
When pulsatile blood flow is noted through the marker
lumen, which indicates the sutures and needles are within
the vessel lumen, all four needles and sutures are deployed
by aligning the barrel and withdrawing the ring (Fig 9). It
is important to maintain the proper amount of tension on
the shaft to avoid compression of the artery during deploy-
ment of the needles, which also ensures that the sutures are
placed adjacent to the arteriotomy and only in the anterior
wall of the artery. The two sutures which are colored white
and green are next separated from the Prostar XL and
placed under towels across the groin (Fig 9). The device is
Fig 7. Deployment of the StarClose closure device. A, The
sheath is introduced first over a wire followed by the StarClose
device that is inserted into the sheath after wire removal. The vessel
locator button is depressed. The device is pulled out until resis-
tance is felt. The advancement of the thumb advancer completes
the splitting of the sheath. The device is raised to an angle of
slightly less than 90°.B,The clip is deployed to catch adventitia for
hemostasis and the device is retracted.removed over the wire, and progressive dilations are per-formed to allow placement of the appropriate-sized sheath
for endograft deployment. The procedure can be repeated
on the opposite groin for the contralateral limb. The oper-
ator has to form the knot in each of the two Prostar XL
sutures using a sliding-knot technique. One end of the
suture is the rail end, which is used to pull the knot all
the way down to the arteriotomy site. The other end, the
non-rail end, is used to lock the knot. A wire is placed in the
monorail side port on the sheath of the device to maintain
arterial access in case of device failure. When the large
introducer sheath is withdrawn, both suture rails are pulled
with tension to slide the knots downward to the femoral
arterial wall (Fig 10). If there is no bleeding, the wire is
removed and a knot pusher (Abbott Vascular Devices,
Abbott Park, Ill) is used to advance the sliding knots to the
vessel wall (Fig 10). Lastly, the non-rail end of the suture is
pulled to lock the knot in place, and the sutures are cut
close to the arterial wall. Standard groin dressings are lastly
applied in bilateral groins. Clinical series using this Prostar
device or double Perclose devices have been reported with
remarkable success rates of 88% to 96% in achieving hemo-
stasis following percutaneous procedures with sheaths
greater than 16F in size.24,25,27-30 All authors from these
clinical series uniformly underscored a clear learning curve
in which early procedure failure is common. With proper
selection of the femoral artery and increased operator’s
experience, endovascular aortic procedures can be achieved
with the percutaneous approach using the Preclose device
with high success rates. In one study looking at early and
midterm outcomes of femoral arteries after PEVAR, at a
mean follow-up of 11.6 months, only 3 (1.92%) patients
required repair of their femoral artery.31 The overall early
technical success was 94.4%, but when looking at different
subsets of sheath sizes, the larger sheaths (18F) had the
lowest technical success at 92.8%.31 In another study com-
paring percutaneous access with femoral cut down for
EVAR, the percutaneous group had lower overall compli-
cations as well as the subset of patients with calcified vessels
and obese patients.32
CLINICAL EXPERIENCE WITH VASCULAR
CLOSURE DEVICES
There is no large randomized study comparing the
different ACD to each other and/or to MC. In one single
institution randomized study involving 705 patients ran-
domized to three ACD (Angio-Seal, VasoSeal, and Duett)
in the setting of diagnostic and percutaneous coronary
intervention (PCI), which requires a larger sheath, all three
devices had a high rate of technical success with surgical
intervention rate of 1%.33 Angio-Seal provided earlier time
to ambulation compared with the other two devices. All
three devices were considered safe; however, the vasoseal
device had a slightly higher rate of complication compared
with the other two in the PCI group.33 In another larger
series evaluating ACD use in the setting of PCI and anti-
coagulation in more than 4500 patients, ACD had a similar
or lower complication rate than MC.34 The two devices
used were Angio-Seal and Perclose.
al com
rocee
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a marginal benefit of ACD over MC at an increased risk of
groin hematoma and pseudoaneurysm.2 As mentioned ear-
lier, this meta-analysis did not look at the heterogeneity of
Fig 8. Deployment of the Boomerang closure device. A
is deployed and opens into a conformable disc. C, The
device is pulled after collapsing the disc, and light manu
Fig 9. Using a Perclose Prostar device in endovascula
femoral artery is confirmed angiographically. B, The 10
under fluoroscopic guidance since the device is long and
is seen, this indicates that the device with its sutures is int
forward pressure to keep the device intraluminal.D, T su
intraluminal position by applying a gentle pull. This mea
a white suture, which are separated and tagged until the
in figure B), a wire is reintroduced to place a sheath to pthe studies, and included reports on the early use of ACDwith lack of operator comfort. Another meta-analysis
looked at comparing ACD (Angio-Seal, Perclose, and
VasoSeal) to MC in the setting of diagnostic angiogram
and PCI in over 37,000 patients. It showed that in the
e wire is inserted through an existing sheath. B, The tip
is removed; this tamponades the arteriotomy. D, The
pression is applied until hemostasis is achieved.
ic stent-grafting procedure. A, Access to the common
star XL is advanced over the wire. This should be done
ip ends up the aortic bifurcation. C,When pulsatile flow
inal. The needles are deployed while maintaining gentle
are deployed around the arteriotomy and are checked for
e sutures did catch the arterial wall. There is a green and
f the case. Prior to removing the device (white tip device
d with PEVAR., Th
sheathr aort
F Pro
the t
ralum
tures
ns th
end osetting of diagnostic angiogram, access-site related compli-
res. D
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ever, in the PCI group, VasoSeal had a higher complication
rate. The overall analysis favored MC over ACD.3
As one of the most widely used closure devices, the
Angio-Seal device has been reported in the literature with
an abundance of clinical experience.35-41 All available stud-
ies cited a high clinical success rate in achieving hemostasis
which ranged from 92% to 98%.35-41 Device failure is
relatively uncommon in the clinical series with high proce-
dural volumes, which ranged from 1% to 3%.35-41 None-
theless, simple application of manual compression would
almost uniformly achieve hemostasis even in the event of
device failure.4,35,40,41 Common modes of device failure
are related to the inability to advance the locator sheath in
a scarred groin or improper anchor positioning which
ultimately resulted in suboptimal application of the colla-
gen plug.14,18,40 Several comparative studies analyzing
Angio-Seal vs manual compression reported shorter time to
hemostasis and ambulation in patients treated with the
Angio-Seal device.42-44 A randomized trial comparing
Angio-Seal with MC showed reduced time to hemostasis
and earlier ambulation in the Angio-Seal group despite
anticoagulation as well as reduced complication.45 In an-
other randomized study comparing Angio-Seal to fem-stop
device, the early benefit of Angio-Seal in the first 2 hours
Fig 10. Using a Perclose Prostar device in endovascu
A,When an endovascular aortic procedure is completed,
for knot tying. The white structure in these figures is the
suture tension, making sure the same colored sutures are t
locks the knot, called the non-rail end, is left alone till
B, Endovascular sheath is removed and both suture rails
to the femoral arterial wall. C, A knot pusher is used w
non-rail suture is pulled to secure the knot on both sutuwith reduced local groin complication was lost at 24 hours.However, the fem-stop group received external compres-
sion only when the ACT was100; meanwhile the Angio-
Seal was deployed regardless of anticoagulation status.46
Inadvertent deployment of an intraluminal collagen
plug can lead to femoral artery occlusion, which is a major
complication with a reported incidence ranging from 0.8%
to 3.6%.35-41,43,44 One can reduce this potential complica-
tion by avoiding placement of the Angio-Seal device in
arteries less than 5 mm in diameter or in arteries with
significant circumferential calcification or thrombus which
may compromise the flow lumen. As with all percutaneous
closure devices, the deployment of the Angio-Seal device in
the common femoral artery can ensure the highest likeli-
hood of clinical success.
The VasoSeal device has similarly endured a high de-
gree of clinical scrutiny in the literature. Numerous clinical
series have reported high technical success rates ranging
from 90% to 100%.4,17,18,33,38,47 In patients who received
systemic anticoagulation, this device remained efficacious
in achieving hemostasis following percutaneous interven-
tions.17,47,48 Several comparative studies between the Va-
soSeal device and manual compression demonstrated no
differences in the rate of femoral artery pseudoaneurysm or
hematoma formation.4,17,18,38,47,48 In the early 1990s,
multiple randomized studies favoredMC over VasoSeal use
rtic stent-grafting procedure (continued from Fig 9).
e-deployed sutures of a Perclose Prostar device are ready
th. Both sutures are pulled upward to create an upward
er. The operator has to form a knot, and one end, which
not is pushed all the way down to the arteriotomy site.
e and green) are pulled gently. This slides the knot down
the sheath is removed. If hemostasis is satisfactory, the
, Once the hemostasis is achieved, extra sutures are cut.lar ao
the pr
shea
ogeth
the k
(whit
henin patients undergoing PCI.49,50 However, other reports
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over MC.51,52 This difference was the result of the multiple
revisions the VasoSeal received. Also, this device requires a
large subcutaneous tract for device deployment. If the
device fails, this could lead to an increase in local vascular
complications.
Early versions of the VasoSeal device were associated
with an increased incidence of groin infection.17,33,47,48
However, subsequent studies based on more recent device
platforms showed no evidence of increased infectious compli-
cations.17,33,47,48 Similar to the Angio-Seal device, which
deploys an extraluminal collagen plug, femoral artery occlu-
sion due to inadvertent intraluminal collagen plug deploy-
ment with the VasoSeal device has been reported.18,53
The clinical efficacy of the Duett device has been assessed
in several studies, which uniformly noted high technical suc-
cess rates which ranged from 93% to 100%.19,54-57 Clinical
studies also demonstrated a faster time to hemostasis and
ambulation in patients treated with the Duett device com-
pared with those treated with manual compression.19,54-57
The efficacy of the Duett device was similarly remarkable
regardless of whether angiographic procedures were per-
formed for diagnostic or therapeutic intent.12,19,20,54-57 Sim-
ilar treatment success was also reported in patients who re-
ceived full anticoagulation.21,54 Other studies noted no
differences in terms of complications, including femoral
artery pseudoaneurysm, hematoma, or groin infection, be-
tween patients treated with the Duett device vs those
treated with manual compression.19,21 In the event of an
unusual complication of a femoral artery thrombosis fol-
lowing the deployment of the Duett device, successful flow
restoration has been reported using catheter-directed
thrombolytic therapy.21,55
As the first approved device using a suture-mediated
technology, the Perclose device was viewed by many as a
technology utilizing many cumbersome steps for suture
deployment and knot creation.While several clinical studies
reported device success rates ranging from 90% to 100%
which is similar to other devices.22,48,58-62 Device failure,
while uncommon, has been attributed to suture breakage
or failure to create a secured knot. If the Perclose device
fails, MC can achieve hemostasis. The device allows for wire
re-introduction while maintaining intraluminal access if it
fails to deploy. Experience with the device and the decision
whether to hold MC or reintroduce the wire requires good
clinical judgment especially in patients with peripheral vas-
cular disease.63 Comparative studies between the Perclose
device vs manual compression noted a faster time to achieve
hemostasis and ambulation when using the Perclose de-
vice.22,48,58-62 There aremultiple small randomized studies
comparing Perclose to MC in the setting of diagnostic
angiography, PCI, and both. The results are mixed; some
favor Perclose with fewer complications41,52,64,65 and oth-
ers favor MC.18,53,66-68 The variety of these results is
related to the evolution of this device; the newer devices are
easier to use with a pre-tied knot. Similar to other devices,
this device can achieve a high degree of success even in
patients who receive anticoagulation.22,48,58-62 An unusualcomplication of femoral arteritis has been reported with
early platform of Perclose device which used a braided
suture.48,69,70 The introduction of the ProGlide model,
which incorporated an improved suture trimming mecha-
nism and replaced braided suture with monofilament
polypropylene suture, has reduced the incidence of device
failure and lowered the risk of infectious complica-
tion.48,69,70
The StarClose device is the most commonly used de-
vice utilizing a metal-based staple technology. Several stud-
ies, which compared the efficacy of this device with manual
compression, found that the StarClose device was associ-
ated with significantly reduced time to hemostasis and
ambulation.35,71-75 A different study, which compared pa-
tients treated with StarClose vs Angio-Seal, found that both
devices had similar efficacy and safety profile in achieving groin
hemostasis.76 However, patients who received the StarClose
device were more likely to require post-deployment manual
compression than those treated with Angio-Seal device.76We
concurwith this finding, and, frompersonal experience, noted
that the nitinol ring was frequently deployed in the subcu-
taneous tissue rather than the adventitia upon femoral
exploration during subsequent revascularizations. The niti-
nol ring misplacement narrowed or compressed the tract
along with external compression hemostasis could still be
achieved.
The use of ACD and their safety is still debatable.
However, like any new technology introduced, it takes time
for the operator to gain experience as well as make the ACD
safer and easier to use. Recent data show that the newer
ACD devices as well as operator experience are associated
with less complications.6,77,78 Also ACD devices could be
safely used in patients with peripheral vascular disease with
no alteration of their ankle-brachial indices.37
Calculating cost-effectiveness is multifactorial, and it is
not known if ACD use is associated with reduced cost. But
it is intuitive that ACD are cost-effective if they are associ-
ated with less vascular complications. Multiple studies have
shown that ACD are associated with decreased hospital
length of stay compared with MC.9,16,78 The biggest ben-
efit would be if these devices could convert therapeutic
interventions to an outpatient procedure. This might be
eventually answered when the use of ACD is reimbursed.
This will provide an incentive for a large randomized study
evaluating their safety and cost-effectiveness compared
with MC.
CONCLUSION
All available current devices have been shown to
shorten time to hemostasis and ambulation compared with
manual compression. These benefits could translate to a
potential decrease in hospital stay and early discharge fol-
lowing percutaneous endovascular procedures. Despite the
clinical efficacy of available closure devices, interventional-
ists must be cognizant that all closure devices are associated
with a definite learning curve. There is no one single device
that is ideally suited for all patients. Familiarity with differ-
ent devices will be helpful in using certain devices in differ-
JOURNAL OF VASCULAR SURGERY
December 20101694 Bechara et alent clinical situations. For instance, the need for immediate
percutaneous access or operative groin intervention may
favor the use of a closure device, which does not utilize
certain collagen-based plugs as the risk of soft tissue inflam-
mation and operative scarring may be significant.
The current available arterial closure devices have made
this technology an essential component of endovascular
clinical practice. Interventionalists should consider all pa-
tients undergoing percutaneous arterial procedure as can-
didates for closure device application. Institutions should
have their own algorithm for ACD use. They should exam-
ine the safety and cost as well as technical success and come
up with an algorithm as to whether to use ACD or MC,
while awaiting a large randomized study that will put these
concerns to rest.
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